Developing SCD1 inhibitors as anticancer agents faces challenges, such as off-target effects and drug resistance. Ongoing research aims to address these issues and further refine the development of SCD1 inhibitors for cancer treatment.
If you need to purchase chemical raw materials, submit your demand information to get the latest quotations.
3-Pyridazinecarbonyl chloride, 1,6-dihydro-6-oxo- (9CI)
3,3-diphenyl-8-hydroxymethyl-[3H]-naphthol[2,1-b]pyran
